Literature DB >> 23232633

Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance.

Xiao-Feng Zhang1, Zheng-Feng Yin, Kui Wang, Zong-Qin Zhang, Hai-Hua Qian, Le-Hua Shi.   

Abstract

BACKGROUND: Alpha-fetoprotein (AFP) is the most established tumor marker of hepatocellular carcinoma (HCC), but one of its limitations is non-specificity. Many studies have demonstrated that alpha-fetoprotein-L3 (AFP-L3) is more specific than AFP in the early diagnosis and prognosis of HCC. However, there is a lack of knowledge about the post-hepatectomy profiles of serum AFP and AFP-L3 values in HCC patients. To identify the profiles after surgical resection of HCC, we analyzed the correlation between the profiles and postoperative HCC recurrence or survival, and evaluated their utility in predicting postoperative therapeutic efficacy and prognosis.
METHODS: From August 2003 to December 2004, 318 patients with positive serum AFP who had received surgical resections were enrolled in this study. Preoperative and postoperative serum AFP and AFP-L3 levels were measured simultaneously and regularly, and their postoperative profiles during a long-term follow-up were recorded and summarized.
RESULTS: A high ratio of AFP-L3 to total AFP was shown to correlate with pathologic features of aggressiveness. The overall 1-, 3-, and 5-year recurrence rates of the whole series were 28%, 57%, and 84%, and the overall survival rates were 86%, 61%, and 33%, respectively. The changes of serum AFP and AFP-L3 after hepatectomy for HCC were classified into 3 groups (group A: AFP-L3 undetectable; group B: AFP-L3 <10%; and group C: AFP-L3 >10%). Patients with positive postoperative AFP-L3 had significantly earlier recurrence than those with negative results. The overall survival was significantly shorter in the positive groups than in the groups negative for postoperative AFP-L3.
CONCLUSION: Post-hepatectomy changes in serum AFP and AFP-L3 levels occurred in three distinct patterns, which were closely correlated with HCC recurrence and patient survival with different prognostic values.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23232633     DOI: 10.1016/s1499-3872(12)60234-3

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  6 in total

1.  Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.

Authors:  Yanfang Zhang; Xuezhong Lei; Liangliang Xu; Xiaoju Lv; Mingqing Xu; Hong Tang
Journal:  BMC Surg       Date:  2022-06-17       Impact factor: 2.030

2.  Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis.

Authors:  Tong-Chun Xue; Lan Zhang; Xiao-Yin Xie; Ning-Ling Ge; Li-Xin Li; Bo-Heng Zhang; Sheng-Long Ye; Zheng-Gang Ren
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

3.  Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  World J Clin Cases       Date:  2018-06-16       Impact factor: 1.337

4.  The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.

Authors:  Bo Li; Aixia Liu; Yi Wen; Guang Yang; Jing Zhao; Xiaohan Li; Yuanli Mao; Boan Li
Journal:  J Clin Lab Anal       Date:  2021-08-17       Impact factor: 2.352

5.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

Review 6.  The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.

Authors:  Taofei Zeng; Yuqing Cao; Tianqiang Jin; Yu Tian; Chaoliu Dai; Feng Xu
Journal:  J Exp Clin Cancer Res       Date:  2021-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.